NRI.TO : Summary for NUVO PHARMACEUTICALS INC - Yahoo Finance

U.S. Markets close in 4 hrs 13 mins

Nuvo Pharmaceuticals Inc. (NRI.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
5.30+0.04 (+0.76%)
As of 9:55AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.26
Open5.30
Bid5.30 x
Ask5.34 x
Day's Range5.30 - 5.30
52 Week Range5.00 - 8.35
Volume354
Avg. Volume20,756
Market Cap61.2M
Beta-0.09
PE Ratio (TTM)14.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Accesswire8 days ago

    Research Reports Initiated on Healthcare Stocks NeutriSci International, Nuvo Pharmaceuticals, Zomedica Pharmaceuticals, and Acerus Pharmaceuticals

    LONDON, UK / ACCESSWIRE / March 15, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...

  • Associated Press22 days ago

    Nuvo Research posts 4Q profit

    On a per-share basis, the Mississauga, Ontario-based company said it had net income of 11 cents. The drugmaker posted revenue of $4.2 million in the period. For the year, the company reported net income ...

  • PR Newswire22 days ago

    Nuvo Pharmaceuticals™ Announces 2016 Year-End and Fourth Quarter Results

    MISSISSAUGA, ON, March 1, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced its financial and operational results for the fourth quarter and year ended December 31, 2016.  For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A) and Consolidated Financial Statements which are available on the Company's website (www.nuvopharmaceuticals.com). In November 2016, the Company commenced a new placebo-controlled, multi-centre Phase 3 trial (2016 Pennsaid 2% Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains.  The 2016 Pennsaid 2% Trial is designed to support regulatory applications for marketing approval of Pennsaid 2% for the treatment of acute pain in the E.U., Canada and Australia.  As of February 27, 2017, 85% of the target number of patients had been enrolled in the study.  Top-line results of the trial are expected to be available in Q2 2017.